Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues
Reports 82% Growth In Q3
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.
You may also be interested in...
Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The company’s semaglutide franchise pushed net sales for the first half of 2021 up 5% year over year at DKK66.8bn ($10.6bn), helped by double- and triple-digit growth for Ozempic and Rybelsus.